Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Kirk perry - The Untold Story

Kimberly-Clark Snaps Up Tylenol Maker Kenvue in £30 Billion Takeover Amid Autism Controversy

Kimberly-Clark to acquire Kenvue, owner of Tylenol, in a £40 billion deal amid controversy over the painkiller's safety concerns and declining sales.

International Business Times UK · Nov 4, 2025

This Billionaire Investor Is ‘Thrilled’ to Own Kenvue Stock Despite Tylenol Turbulence. Should You Buy KVUE Here?

Kenvue stock is down 28% in 2025 amid controversy surrounding its Tylenol brand, which is linked to autism when used during pregnancy.

Barchart · Oct 22, 2025

'This team is guided by science': Kenvue chief hits back at Trump and RFK Jr.'s Tylenol autism claims in memo to 20,000 employees

Promotion of unproven claims from President Trump and RFK Jr. linking acetaminophen (Tylenol) to autism have significantly impacted Kenvue’s business.

Fortune · Oct 1, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

RFK Jr. wanted to blame Tylenol for autism after meeting with drugmaker CEO

Trump was eager to single out drug manufacturer despite no new evidence to support administration’s unproven claims

The Independent UK · Sep 25, 2025

As Trump Takes Aim at Tylenol, Should You Buy, Sell, or Hold Parent Company Kenvue Stock’s Here?

Kenvue stock is trailing the broader markets by a wide margin in 2025 due to regulatory concerns over its flagship Tylenol product.

Barchart · Sep 24, 2025

Kenvue Pushes To Defend Pain Killer Tylenol Against Autism Claims Ahead Of Government Report

Kenvue Inc. (NYSE:KVUE) interim CEO Kirk Perry met privately this week with Health Secretary Robert F. Kennedy Jr. to argue that there is no proven link between the popular pain reliever Tylenol and autism.

Benzinga · Sep 12, 2025

Tylenol-Maker Kenvue Launches Turnaround Plans. How Should You Play KVUE Stock Here?

Kenvue Inc ousted its chief executive and announced a strategic review on Monday. Jefferies says KVUE shares could rally to $27.

Barchart · Jul 14, 2025

Read news from The Economist, FT, and more,
with one subscription

Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors

The company will likely focus on off-loading smaller beauty brands.

Fortune · Jul 14, 2025

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.